Equities research analysts expect Shire PLC (NASDAQ:SHPG) to report earnings of $3.22 per share for the current quarter, Zacks reports. Five analysts have made estimates for Shire PLC’s earnings, with the lowest EPS estimate coming in at $2.70 and the highest estimate coming in at $3.40. Shire PLC posted earnings per share of $3.19 during the same quarter last year, which suggests a positive year-over-year growth rate of 0.9%. The company is scheduled to announce its next earnings results before the market opens on Tuesday, May 2nd.
On average, analysts expect that Shire PLC will report full year earnings of $15.00 per share for the current year, with EPS estimates ranging from $14.75 to $15.20. For the next year, analysts forecast that the firm will post earnings of $17.36 per share, with EPS estimates ranging from $16.16 to $18.38. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Shire PLC.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.24 by $0.13. Shire PLC had a net margin of 1.62% and a return on equity of 14.81%. The firm earned $3.81 billion during the quarter, compared to the consensus estimate of $3.78 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The company’s revenue was up 121.8% on a year-over-year basis.
SHPG has been the topic of a number of research reports. Jefferies Group LLC set a $239.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a report on Thursday, April 20th. Royal Bank of Canada reiterated a “buy” rating and set a $221.00 target price on shares of Shire PLC in a report on Tuesday, March 14th. Liberum Capital initiated coverage on shares of Shire PLC in a report on Thursday, March 9th. They set a “buy” rating on the stock. Goldman Sachs Group Inc reiterated a “conviction-buy” rating on shares of Shire PLC in a report on Friday, April 14th. Finally, Guggenheim reiterated a “neutral” rating on shares of Shire PLC in a report on Friday, February 17th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $221.70.
Shire PLC (NASDAQ:SHPG) traded down 0.49% during mid-day trading on Thursday, hitting $176.96. 613,742 shares of the stock traded hands. The stock has a market cap of $52.71 billion, a P/E ratio of 142.48 and a beta of 1.53. Shire PLC has a 12 month low of $161.09 and a 12 month high of $209.22. The stock has a 50-day moving average price of $174.78 and a 200-day moving average price of $174.73.
The business also recently declared a dividend, which was paid on Tuesday, April 25th. Investors of record on Friday, March 10th were paid a dividend of $0.771 per share. This is a positive change from Shire PLC’s previous dividend of $0.14. The ex-dividend date was Wednesday, March 8th. Shire PLC’s dividend payout ratio (DPR) is currently 51.95%.
A number of large investors have recently made changes to their positions in the company. Norges Bank bought a new stake in shares of Shire PLC during the fourth quarter valued at approximately $160,922,000. Price T Rowe Associates Inc. MD raised its stake in shares of Shire PLC by 20.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 4,781,923 shares of the biopharmaceutical company’s stock valued at $927,024,000 after buying an additional 802,411 shares in the last quarter. York Capital Management Global Advisors LLC bought a new stake in shares of Shire PLC during the third quarter valued at approximately $100,021,000. The Manufacturers Life Insurance Company bought a new stake in shares of Shire PLC during the third quarter valued at approximately $89,175,000. Finally, Janus Capital Management LLC raised its stake in shares of Shire PLC by 34.6% in the fourth quarter. Janus Capital Management LLC now owns 1,232,780 shares of the biopharmaceutical company’s stock valued at $210,063,000 after buying an additional 317,066 shares in the last quarter. Hedge funds and other institutional investors own 22.69% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/05/20/3-22-eps-expected-for-shire-plc-shpg-this-quarter-updated-updated.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.